Table 3 Comparison of the clinical characteristics according to the ILD Severity

Age, n

≥ 65

25

14

0.196

< 65

5

7

Sex, n

Male

28

19

1.000

Female

2

2

Anti-PD-1/PD-L1 antibody, n

Nivolumab

19

9

0.148

Pembrolizumab

7

8

0.351

Atezolizumab

1

3

0.293

Durvalumab

3

1

0.635

Combination, n

Chemotherapy

2

2

1.000

Anti-PD-1/PD-L1 antibody duration until ILD onset (cycles), median (range)

4.5 (1–71)

3.0 (1–13)

0.147

Cancer type, n

Lung cancer

21

16

0.754

Other cancer

9

5

Malignant melanoma

3

1

-

Gastric cancer

1

0

-

Bladder cancer

0

3

-

Kidney cancer

1

0

-

Head and neck cancer

2

1

-

Esophageal cancer

2

0

-

Laboratory test, median (range)

Onset CRP

2.50 (0.10–22.00)

8.50 (1.10–23.10)

0.004

Onset NLR

5.45 (1.21–24.57)

11.09 (3.35-99.00)

0.002

Onset dNLR

2.91 (0.73–9.99)

5.07 (2.03-99.00)

0.002

Onset LMR

21.63 (0.40–5.56)

1.36 (0.25-7.00)

0.276